resulted in reallocation between sales and service revenue as well as marketing expenses while device subsidy is capitalized as contract assets and amortized against the service revenue over the customer

for users. Given an early stage of 5G technology, there are currently 16 models of 5G device with starting price over Bt10,000. Hence, adoption rate is expected to be limited this year. We continued to

under other service revenues and device sales. As the acquisition value was higher than CSL’s net identifiable assets, AIS recognized the value difference as goodwill amounting to Bt2.8bn. With the

Reporting Standards (TFRS) 9 regarding Financial Instruments and TFRS 16 regarding Leases since 1 Jan 2020. TFRS 9: Financial Instrument The standard requires financial instruments to be classified into three

strategy is the key tool for this industry. According to performance loss and franchise model concept, it affects with significant drop of the business valuation of the subsidiary company. In 2017, the

the key tool for this industry. According to performance loss and franchise model concept, it affects with significant drop of the business valuation of the subsidiary company. In 2017, the Company has

contract term, profitability of the contract remains the same. By the Standard, key changes compared to prior to 2019, are as follows: a) Device subsidy previously recognized as handset loss will be

, medical device business is expected to be growth at an average rate of 8.5-10.0% per year. This growth will be supported by: (i) government policy, focused on promoting investment in the sector through the

1,921 million decreased by 7% compared to the previous year. It derived from: • Revenues from sales and services of medical device business for the year 2019 were Baht 1,798 million decreased by 3% in

169 163 151 148 136 Blended 186 181 170 168 156 VOU (GB/data sub/month) Postpaid 6.7 7.5 8.3 9.2 10.9 Prepaid 4.1 5.4 6.2 7.0 8.2 Blended 4.7 5.9 6.7 7.6 8.9 Device Penetration 4G-handset penetration 39